COMParison of the EffecT of dEvice Closure in Alleviating Migraine With PFO (COMPETE-2)
Comparison of the Effect of Device Closure in Alleviating Migraine With Patent Foramen Oval (COMPETE-2)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Xiangbin Pan, MD
- Phone Number: 88396666
- Email: panxiangbin@fuwaihospital.org
Study Contact Backup
- Name: Fengwen Zhang, MD
- Phone Number: 88396666
- Email: zhangfengwen08@126.com
Study Locations
-
-
Beijing
-
Beijing, Beijing, China
- Recruiting
- Fuwai Hospital
-
Contact:
- Xiangbin Pan, MD
- Phone Number: 88396666
- Email: panxiangbin@fuwaihospital.org
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-65 ;
- Diagnosed migraine by ICHD-3
- History of migraine longer than 1 year
- TCD/TTE/TEE diagnosed patent foramen ovale
- Willing to participant and agree to follow-ups
- Undertook medication therapy for three months without a responder rate higher or equal to 50%
Exclusion Criteria:
- Migraine caused by other reason
- Had TIA/stroke history
- Hypersensitive or hyposensitive to the study drug
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PFO closure
|
Participants randomized into this group will take PFO device closure.
|
|
Sham Comparator: Shame procedure
|
Participants randomized into this group will take aspirin 200mg qd for 6 months.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Responder rate
Time Frame: From baseline period to 12-month treatment period
|
Defined as a 50% reduction from the monthly number of migraine attacks during the baseline phase to the monthly number of migraine attacks during the treatment phase.
|
From baseline period to 12-month treatment period
|
|
Treatment safety
Time Frame: From baseline period to 12-month treatment period
|
Adverse events after medication treatment Adverse events after medication treatment Adverse events after medication treatment Adverse events after medication treatment Adverse events after medication treatment |
From baseline period to 12-month treatment period
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Migraine days change per month
Time Frame: From baseline period to 12-month treatment period
|
Change in the mean number of migraine days from baseline to treatment phase.
|
From baseline period to 12-month treatment period
|
|
Number of migraine attacks change per month
Time Frame: From baseline period to 12-month treatment period
|
Change in the mean number of migraine attacks from baseline to treatment phase.
|
From baseline period to 12-month treatment period
|
|
Percentage of migraine change
Time Frame: From baseline period to 12-month treatment period
|
Participants experienced 75%, or greater reduction in migraine headache attacks during treatment phase as compared to baseline phase.
|
From baseline period to 12-month treatment period
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Congenital Abnormalities
- Headache Disorders, Primary
- Headache Disorders
- Heart Defects, Congenital
- Cardiovascular Abnormalities
- Heart Septal Defects, Atrial
- Heart Septal Defects
- Migraine Disorders
- Foramen Ovale, Patent
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
Other Study ID Numbers
- 2022-1748
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.